//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Subcutaneous blinatumomab led to high response rates across 2 dosing regimens in heavily pretreated patients with relapsed/refractory, Ph-positive B-ALL in a phase 1/2 trial #EHA2026 #leusm #oncology Dive into the data: www.onclive.com/view/subcuta...
16h
Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.
www.onclive.com
Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL | OncLive
OncLive